This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioCryst Pharmaceuticals’s 8K filing here.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Read More
- Five stocks we like better than BioCryst Pharmaceuticals
- ETF Screener: Uses and Step-by-Step Guide
- 3 Smart Picks: Discounted Stocks for Savvy Investors
- 3 Grocery Stocks That Are Proving They Are Still Essential
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
- Buy P&G Now, Before It Sets A New All-Time High
- Why AMD Stock Might Already Be This Year’s Best Buy
